✦ LIBER ✦

PDB27 A COST-UTILITY ANALYSIS OF ORLISTAT (XENICAL®) IN THE TREATMENT OF DIABETIC PATIENTS WITH MORBID OBESITY AND ADDITIONAL CVD RISK IN NORWAY

✍ Scribed by JM Sverre; FKO Kristensen; LB Holm; K Nyhus

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDB21 A COST-UTILITY ANALYSIS OF INSULIN

✍ FK Kristensen; JM Sverre; S Bustad 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PDB40 COST-UTILITY ANALYSIS IN A USA SET

✍ AJ Palmer; R Chen; WJ Valentine; S Roze; S Gabriel; N Mehin; B Bregman; R Rodby 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

PCV45 COST-UTILITY ANALYSIS OF RIMONABAN

✍ B Nagy; K Borsos; G Blaskó 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PDB24 A COST-EFFECTIVENESS ANALYSIS OF I

✍ TJ Lee; DS Han; HS Sohn 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PCN67 COST UTILITY ANALYSIS OF ALEMTUZUM

✍ AC Lloyd; A Valderrama; J Ferguson; L Gilmour; F Ravndal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

PUK11 A COST-UTILITY ANALYSIS OF SOLIFEN

✍ L Cardozo; A Thorpe; M Grishchenko; MK Sidhu 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB